Becton, Dickinson and Company (NYSE:BDX – Get Free Report) has been given an average rating of “Moderate Buy” by the eighteen research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $185.07.
Several research firms have weighed in on BDX. Zacks Research upgraded Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Weiss Ratings raised Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Wells Fargo & Company increased their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Finally, Royal Bank Of Canada raised their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th.
Check Out Our Latest Research Report on Becton, Dickinson and Company
Becton, Dickinson and Company Trading Down 1.4%
Shares of BDX opened at $196.11 on Tuesday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm’s 50-day moving average is $185.38 and its two-hundred day moving average is $170.44. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $200.47. The firm has a market capitalization of $54.04 billion, a P/E ratio of 15.30, a PEG ratio of 13.41 and a beta of 0.21.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the company posted $3.68 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.
Insider Buying and Selling at Becton, Dickinson and Company
In other news, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,831 shares of company stock valued at $1,254,070 over the last quarter. Corporate insiders own 0.40% of the company’s stock.
Institutional Investors Weigh In On Becton, Dickinson and Company
A number of large investors have recently bought and sold shares of BDX. BlackRock Inc. purchased a new stake in Becton, Dickinson and Company during the 2nd quarter worth about $3,721,533,000. State Street Corp lifted its holdings in Becton, Dickinson and Company by 8.5% in the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock valued at $2,269,960,000 after purchasing an additional 1,177,256 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in shares of Becton, Dickinson and Company by 15.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth about $474,993,000. Finally, Legal & General Group Plc grew its holdings in shares of Becton, Dickinson and Company by 1.5% during the second quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier’s stock worth $318,050,000 after buying an additional 30,766 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.
BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
